Stay updated on Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedCore page content identifying investigators, sponsor, collaborators, and other study personnel was removed, along with multiple study record metadata sections. A new Revision: v3.6.5 tag appears, indicating a version update to the page.SummaryDifference17%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page's revision version was updated from v3.6.3 to v3.6.4, indicating a new deployment. This update does not modify the study details or functionality presented to users.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page version was updated from v3.6.2 to v3.6.3. This represents a routine update that does not alter study information or how a user interacts with the page.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page footer now shows Revision: v3.6.2, replacing the previous Revision: v3.6.0; this indicates a new build of the page template rather than substantive changes to the study information.SummaryDifference0.1%

- Check75 days agoChange DetectedA recruitment status line indicating no participant enrollment was added. Additionally, new help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), the Interventional label formatting was refined from 'Intervention / Treatment' to 'Intervention/Treatment', and a site revision stamp 'Revision: v3.6.0' was introduced.SummaryDifference0.6%

- Check82 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5. This reflects a metadata version bump for the study page rather than any substantive alteration to the study details.SummaryDifference0.1%

Stay in the know with updates to Grapiprant and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Grapiprant and Pembrolizumab in NSCLC Clinical Trial page.